Antibiotic Choice for Community-Acquired Pneumonia in Children With Medical Complexity.

Authors

Maheswari Ekambaram, Yun Li, Joanna Thomson, Jeffrey S Gerber, Kathleen Chiotos

Published in

Pediatrics. Oct 07, 2026. Epub Oct 07, 2026.

Abstract

There are no guideline recommendations for antibiotic choice for community-acquired pneumonia (CAP) in children with medical complexity (CMC). We compared broad- vs narrow-spectrum antibiotics in CMC hospitalized with nonsevere CAP.
This cohort study was conducted using target trial emulation within an academic health system. We included hospitalizations from January 2016 to April 2024 with International Classification of Diseases, 10th Revision (ICD-10) codes for CAP and complex chronic conditions among children aged 3 months to 21 years who received 3 or more days of antibiotics. We excluded children with severe/complicated CAP, chronic pulmonary conditions, sickle cell disease, tracheostomies, immunosuppression, other bacterial infections, or recent CAP admission. The exposure was initial broad-spectrum antibiotics (CAP antibiotics other than aminopenicillins) within 12 hours of presentation. The primary outcome was time to discharge, censored at day 10. Secondary outcomes were progression to severe CAP and 30-day CAP-related revisits. To mitigate confounding, we applied inverse probability of treatment weighting in outcome models, including a Royston-Parmar flexible survival model for time to discharge, and logistic regression for binary outcomes.
A total of 847 encounters (749 patients) were included. After weighting and trimming, 742 encounters remained with adequate covariate balance. Compared with the narrow-spectrum group, the broad-spectrum group demonstrated no significant differences in time to discharge (hazard ratio, 0.84; 95% CI, 0.68-1.04), progression to severe CAP (odds ratio [OR], 1.29; 95% CI, 0.7-2.4), or 30-day CAP-related revisits (OR, 0.39; 95% CI, 0.1-1.2).
In CMC hospitalized with nonsevere CAP, initial broad-spectrum antibiotics did not improve clinical outcomes compared with narrow-spectrum antibiotics, supporting the use of aminopenicillins for nonsevere CAP in many CMC.

PMID:
42838530
Bibliographic data and abstract were imported from PubMed on 07 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.